The present study is an investigator initiated, single-centre, prospective, proof-of-concept cohort study aiming to enroll 44 patients with acute middle cerebral artery (MCA) ischemic stroke, involving the right (n=22) and left (n=22) MCA territories and 24 control patients with acute focal neurological symptoms but no evidence of acute brain infarct on DWI-MRI.
The present study is an investigator-initiated, single-center, prospective cohort study. The study aims to enroll 44 patients with acute/subacute middle cerebral artery (MCA) ischemic stroke. The investigators will compare inflammatory markers among 44 patients with MCA ischemic stroke within 10 days post-stroke vs. 60±15 days post-stroke. Other measures to be determined at both time points include B-Type Natriuretic Peptide and systemic inflammatory markers.
Study Type
OBSERVATIONAL
Enrollment
44
Cardiac magnetic resonance imaging (MRI) with a protocol designed to measure myocardial inflammation and fibrosis.
Measurement of B Natriuretic Peptide on patients' blood samples at 10 and 60+/-15 days.
Measurement of a panel of 92 systemic inflammatory markers on patients' blood samples at 10 and 60+/-15 days.
Heart & Brain Lab, Western University
London, Ontario, Canada
RECRUITINGThe severity of left ventricular myocardial inflammation on cardiac MRI within 10 days post-stroke
Proportion of left ventricular myocardium showing inflammatory changes on gadolinium-enhanced cardiac MRI
Time frame: Within 10 days of stroke onset
The extent of left ventricular fibrosis measured on gadolinium-enhanced cardiac MRI within 10 days of stroke onset
Proportion of left ventricular myocardium showing fibrosis on gadolinium-enhanced cardiac MRI
Time frame: Within 10 days of stroke onset
Changes in left ventricular inflammation measured on gadolinium-enhanced cardiac MRI at 10 and 60±15 days post-stroke
Quantification of left ventricular inflammation measured on gadolinium-enhanced cardiac MRI
Time frame: At 60±15 days compared to first 10 days
Change in B-Type Natriuretic Peptide (NT-proBNP) levels in the second measurement performed at 60±15 days post-stroke relative to the plasma sample drawn within 10 days.
Change in levels of NT-proBNP between 10 and 60±15 days post-stroke
Time frame: At 60±15 days compared to first 10 days
Change in systemic inflammatory markers between 10 and 60±15 days post-stroke
High-performance protein biomarker panel for following 92 inflammatory biomarkers in pg/mL ADA; ARTN; AXIN1; NGF; CCL13; CCL19; CCL2; CCL20; CCL23; CCL25; CCL28; CCL3; CCL4; CCL7; CCL8; CXCL10; CXCL11; CXCL5; CXCL6; CXCL9; CDCP1; CASP8; CST5; DNER; CCL11; EIF4EBP1; FGF19; FGF21; FGF23; FGF5; FLT3LG; CX3CL1; GDNF; CXCL1; HGF; IFNG; IL1A; IL10; IL10RA; IL10RB; IL12B; IL13; IL15RA; IL17A; IL17C; IL18; IL18R1; IL2; IL2RB; IL20; IL20RA; IL22RA1; IL24; IL33; IL4; IL5; IL6; IL7; CXCL8; MMP1; KITLG; LIF; LIFR; LTA; CSF1; SIRT2; CD244;NTF3;NRTN;OSM;CD274;S100A12;TGFA;STAMBP;SLAMF1;MMP10;SULT1A1;CD6;CD5;CD8A;TSLP;TGFB1;TNF;TNFSF10;TNFSF11;TNFSF12;TNFSF14;TNFRSF11B;CD40;TNFRSF9;PLAU;VEGFA
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: At 60±15 days compared to first 10 days
Changes in left atrial inflammation measured on gadolinium-enhanced cardiac MRI at 10 and 60±15 days post-stroke
Quantification of left atrial inflammation measured on gadolinium-enhanced cardiac MRI
Time frame: At 60±15 days compared to first 10 days
Changes in left atrial fibrosis measured on gadolinium-enhanced cardiac MRI at 10 and 60±15 days post-stroke
Quantification of left atrial fibrosis measured on gadolinium-enhanced cardiac MRI
Time frame: At 60±15 days compared to first 10 days